PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

News | PET-CT
Canon Medical’s Digital PET/CT System Receives FDA Clearance

June 10, 2021 — Bringing the power of artificial intelligence (AI) to molecular imaging, Advanced intelligent Clear-IQ ...

Time June 10, 2021
arrow
The U.S. Food and Drug Administration (#FDA) approved #Aduhelm (#aducanumab) for the treatment of #Alzheimer’s, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.
News | PET Imaging
FDA Grants Accelerated Approval for Alzheimer’s Drug Aduhelm

June 7, 2021 — The U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) for the treatment of Alzheimer ...

Time June 07, 2021
arrow
Winship Cancer Institute of Emory University’s EMPIRE-1 trial is first-of-its-kind randomized patient outcomes study of amino acid PET imaging in influencing a cancer control endpoint
News | Radiation Therapy
Results Published for Axumin (Fluciclovine F 18) PET Imaging Study Demonstrating Improved Patient Outcomes in Patients with Recurrent Prostate Cancer

May 25, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 25, 2021
arrow
According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary lymph node or ipsilateral deltoid uptake is occasionally observed on FDG or 11C-choline PET performed after Pfizer-BioNTech or Moderna COVID-19 vaccination
News | Coronavirus (COVID-19)
Nodal and Deltoid Radiotracer Uptake on Post-COVID-19 Vaccination PET

May 19, 2021 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), increased axillary ...

Time May 19, 2021
arrow
Videos | Coronavirus (COVID-19)
VIDEO: COVID Vaccine Adenopathy Can Last Up to 10 Weeks

Yael Eshet, M.D., MSc, a diagnostic radiology specialist at Sheba Medical Center in Israel, was the lead author on a ...

Time May 11, 2021
arrow
GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18)
News | PET Imaging
GE Healthcare Acquires Zionexa

May 6, 2021 — GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology ...

Time May 06, 2021
arrow
After radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by
News | PET Imaging
PET Imaging Adds Valuable Information to Brain Metastasis Monitoring

May 5, 2021 — For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable ...

Time May 05, 2021
arrow
olecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953,113. The patent claims a quick (5 min), easy and quantitative conversion of commercially available 18F-deoxyglucose (18F-FDG) to 18F-Fluroglucaric acid (18F-FGA).
News | PET Imaging
Molecular Targeting Technologies, Inc. Announces New PET Imaging Agent

April 19, 2021 — Molecular Targeting Technologies, Inc. (MTTI) announced the issuance of United States Patent # 10,953 ...

Time April 19, 2021
arrow
The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen
News | PET Imaging
Promising Results from First-in-humans Study of a Novel PET Radiopharmaceutical

April 19, 2021 — The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed ...

Time April 19, 2021
arrow
News | PET-CT
PET/CT Shows Stressed Brain Linked to Broken Heart

March 29, 2021 — Heightened activity in the brain, caused by stressful events, is linked to the risk of developing a ...

Time March 29, 2021
arrow
Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph Vision Quadra, a positron emission tomography/computed tomography (PET/CT) scanner designed for clinical use as well as translational research – or the application of scientific research to create therapies and procedures that improve health outcomes. In this manner, the Biograph Vision Quadra expands precision medicine.
News | PET-CT
Siemens Healthineers Announces FDA Clearance of Biograph Vision Quadra Extended Axial FoV PET/CT Scanner

March 8, 2021 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the Biograph ...

Time March 08, 2021
arrow
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Feature | Treatment Planning | By Melinda Taschetta-Millane
Using PET to Enhance Prostate Treatment Planning

The decision to offer radiation after prostatectomy for patients with recurrent prostate cancer is quite complex, and ...

Time March 05, 2021
arrow
Findings indicate that PPC and GG are highly predictive of overall upstaging by PSMA PET/CT for patients with high-risk prostate cancer
News | PET-CT
Model Helps Predict Which Patients will Benefit Most from PSMA PET Scan

February 23, 2021 — A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which ...

Time February 23, 2021
arrow
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.
News | Molecular Imaging
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment

February 22, 2021 — Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2 ...

Time February 22, 2021
arrow
Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small study, researchers at Washington University School of Medicine in St. Louis found that only women whose tumors responded to estrogen challenge benefited from hormone therapy. The findings could help doctors choose the treatments most likely to help their patients. Image courtesy of Farrokh Dehdashti
News | PET Imaging
Imaging Identifies Breast Cancer Patients Unlikely to Benefit from Hormone Therapy

February 3, 2021 — Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry ...

Time February 03, 2021
arrow
NMP to evaluate technology to create new class of PET radiopharmaceuticals
News | PET Imaging
Fuzionaire Radioisotope Technologies K.K. and Nihon Medi-Physics Enter Feasibility Study Agreement

January 29, 2021 — Fuzionaire Radioisotope Technologies K.K. (“FRIT”) announced that it has entered into a feasibility ...

Time January 29, 2021
arrow
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
News | PET Imaging
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases

January 18, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time January 18, 2021
arrow
Differences in brain activity between connected and disconnected states of consciousness studied with positron emission tomography (PET) imaging. Activity of the thalamus, anterior (ACC) and posterior cingulate cortices (PCC), and bilateral angular gyri (AG) show the most consistent associa-tions with the state of consciousness (A = general anesthesia, B = sleep). The same brain struc-tures, which are deactivated when the state of consciousness changes to disconnected in general anesthesia or natural sleep
News | PET Imaging
Imaging the Twilight Zone

December 30, 2020 — What happens in the brain when our conscious awareness fades during general anesthesia and normal ...

Time December 30, 2020
arrow
A multidisciplinary team of researchers have demonstrated production, purification, and potential for the 134Ce/134La in vivo generator as a PET imaging surrogate for 225Ac and 227Th radiotherapeutic agents.
News | Nuclear Imaging
New Diagnostic Isotope to Enhance Targeted Alpha Therapy for Cancer

December 22, 2020 — Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a ...

Time December 22, 2020
arrow
CXCR4-directed PET correlates with MRI-determined lymphoma lesions. Depicted are representative MR images (T1c- and FLAIR- sequences), and the corresponding CXCR4- directed PET images and fusion images (MRI-FLAIR and PET), of two patients with PCNSL and SCNSL, respectively. Images created by Department of Nuclear Medicine, School of Medicine, Technische Universität München, Munich, Germany.
News | PET Imaging
PET Imaging Tracer Effective for Diagnosing and Managing Rare CNS B-cell Lymphoma

December 14, 2020 — Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for ...

Time December 14, 2020
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now